A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy

Toni K. Choueiri,Michael B. Atkins,Tracy L. Rose,Robert S. Alter,Yawen Ju,Katie Niland,Yan Wang, Robert Arbeit,Sudha Parasuraman,Lu Gan,David F. McDermott

INVESTIGATIONAL NEW DRUGS（2021）

引用 22|浏览3
暂无评分
关键词
CXCR4, Mavorixafor, X4P-001, Renal cell carcinoma, Tumor microenvironment, Nivolumab, Immune therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要